Hsbc Holdings PLC cut its position in Athenex Inc (NASDAQ:ATNX) by 11.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,063,268 shares of the company’s stock after selling 136,597 shares during the period. Hsbc Holdings PLC owned 1.59% of Athenex worth $16,523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of the company. Strs Ohio boosted its stake in Athenex by 9.9% during the second quarter. Strs Ohio now owns 43,400 shares of the company’s stock worth $809,000 after buying an additional 3,900 shares during the last quarter. Legal & General Group Plc boosted its stake in Athenex by 363.2% during the second quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after buying an additional 5,434 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in Athenex during the second quarter worth $266,000. Bank of America Corp DE boosted its stake in Athenex by 34.4% during the second quarter. Bank of America Corp DE now owns 56,822 shares of the company’s stock worth $1,060,000 after buying an additional 14,530 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new position in Athenex during the second quarter worth $294,000. 25.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Athenex stock opened at $13.22 on Monday. Athenex Inc has a 52 week low of $9.83 and a 52 week high of $20.90. The firm has a market capitalization of $884.34 million, a PE ratio of -5.70 and a beta of 0.37. The company has a current ratio of 4.46, a quick ratio of 3.86 and a debt-to-equity ratio of 0.30.
ATNX has been the topic of several recent analyst reports. ValuEngine lowered Athenex from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. Zacks Investment Research lowered Athenex from a “hold” rating to a “sell” rating in a research note on Friday, August 17th. LADENBURG THALM/SH SH initiated coverage on Athenex in a research note on Thursday, October 25th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, JPMorgan Chase & Co. raised Athenex from a “neutral” rating to an “overweight” rating and decreased their price target for the company from $24.00 to $15.00 in a research note on Thursday, November 15th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $22.00.
In other news, insider Jeffrey Yordon acquired 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The shares were purchased at an average price of $10.49 per share, for a total transaction of $99,655.00. Following the acquisition, the insider now owns 198,209 shares of the company’s stock, valued at $2,079,212.41. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Johnson Yiu Nam Lau acquired 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The stock was purchased at an average price of $10.47 per share, for a total transaction of $418,800.00. Following the acquisition, the chief executive officer now directly owns 2,887,422 shares in the company, valued at approximately $30,231,308.34. The disclosure for this purchase can be found here. Insiders purchased a total of 93,500 shares of company stock worth $1,081,935 in the last quarter. Company insiders own 29.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Athenex Inc (ATNX) Shares Sold by Hsbc Holdings PLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2018/12/03/athenex-inc-atnx-shares-sold-by-hsbc-holdings-plc.html.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.